05/26/22 5:26 PMNasdaq : AURA clinical triallow floatAura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual MeetingAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the publication of preclinical data on AU-011, its first VDC product candidate, in combination with immune checkpoint inhibitors. Cadmus Rich, Chief Medical officer and Head of...RHEA-AIneutral
05/25/22 7:00 AMNasdaq : AURA conferenceslow floatAura Biosciences to Participate in Upcoming Investor ConferencesAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that members of its executive team will participate in the following upcoming investor conferences:. Cowen’ s Virtual 3 rd Annual Oncology Innovation Summit on Thursday, June 2,...RHEA-AIneutral
05/12/22 4:15 PMNasdaq : AURA earningsclinical triallow floatAura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational HighlightsAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2022, and provided clinical development and operational highlights. Orphan Drug Designation was recently granted to...RHEA-AIvery positive
05/03/22 4:05 PMNasdaq : AURA clinical triallow floatAura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual MeetingAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU‑ 011. The results were presented as part of the 2022 Association of Research in Vision and...RHEA-AIneutral
05/03/22 7:00 AMNasdaq : AURA conferenceslow floatAura Biosciences to Present at the 2022 Bank of America Healthcare ConferenceAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022 Bank of America Healthcare Conference. The conference is being held in Las Vegas, Nevada...RHEA-AIneutral
03/23/22 4:15 PMNasdaq : AURA earningsclinical triallow floatAura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational HighlightsAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided clinical development and operational highlights. We look forward to initiating the...RHEA-AIvery positive
03/21/22 7:00 AMNasdaq : AURA low floatAura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC product candidate, for the treatment of uveal melanoma. “There are currently no...RHEA-AIvery positive
03/15/22 7:00 AMNasdaq : AURA conferenceslow floatAura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced it will host a virtual Investor Day on Tuesday, March 22, 2022, from 11:00 a.m. to 12:30 p.m. Eastern Time. Carol Shields, MD, Chief of the Ocular Oncology Service at Wills Eye...RHEA-AIneutral
03/08/22 4:30 PMNasdaq : AURA conferencesclinical triallow floatAura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual MeetingAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the presentation of preclinical data for its first VDC product candidate, AU-011 which is being developed for the treatment of life-threatening cancers with high unmet need,...RHEA-AIneutral
02/28/22 7:00 AMNasdaq : AURA conferenceslow floatAura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care ConferenceAura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in the“ Auditory and Ophthalmology” panel discussion at the 42 nd Annual Cowen Virtual Health...RHEA-AIneutral